Cited by 210Lung Cancer Treatments and MutationsCancer Immunotherapy and BiomarkersHER2/EGFR in Cancer Research

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

Open access

Yang, James Chih-Hsin, Shepherd, Frances A., Kim, Dong-Wan, Lee, Gyeong-Won, Lee, Jong Seok, Chang, Gee-Chen, Lee, Sung Sook, Wei, Yu-Feng, Lee, Yun Gyoo, Laus, Gianluca, Collins, Barbara, Pisetzky, Francesca, Horn, Leora·2019·Journal of Thoracic Oncology

DOI 10.1016/j.jtho.2019.02.001

Open this paper in CoChat — free account Open PDF

Abstract

INTRODUCTION: Osimertinib is a third-generation EGFR-tyrosine kinase inhibitor (TKI). Durvalumab is an anti-programmed death ligand 1 monoclonal antibody. The phase III open-label CAURAL trial (NCT02454933) investigated osimertinib plus durvalumab versus osimertinib monotherapy in patients with EGFR-TKI sensitizing and EGFR T790M mutation-positive advanced NSCLC and disease progression after EGFR-TKI therapy. METHODS: Patients were randomly assigned 1:1 to receive orally administered osimertinib (80 mg once daily) with or without durvalumab (10 mg/kg administered intravenously every 2 weeks) until progression. Treatment could continue beyond progression, providing clinical benefit continued (judged by the investigator). The amended primary objective was to assess the safety and tolerability of osimertinib plus durvalumab; efficacy was an exploratory objective. RESULTS: CAURAL recruitment was terminated early because of increased incidence of interstitial lung disease-like events in the osimertinib plus durvalumab arm from the separate phase Ib TATTON trial (NCT02143466). At termination of CAURAL recruitment, 15 patients had been randomly assigned to treatment with osimertinib and 14 to treatment with osimertinib plus durvalumab. The most common AEs were diarrhea (53% [grade ≥3 in 6% of patients]) in the osimertinib arm and rash (67% [grade ≥3 in 0 patients]) in the combination arm. One patient who had been randomized to the combination arm reported grade 2 interstitial lung disease while receiving osimertinib monotherapy (after discontinuing durvalumab therapy after one dose). The objective response rates were 80% in the osimertinib arm and 64% in the combination arm. CONCLUSION: Limited patient numbers preclude formal safety and efficacy comparisons between the two treatment arms. The combination of programmed cell death 1/programmed death ligand 1 inhibitors and EGFR-TKIs as therapy for NSCLC is not well understood, but it requires a careful approach if considered in the future.

Integrity signals

Registry

Crossref · 10.1016/j.jtho.2019.02.001

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Self-citation
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Self-citation
Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Novello, S., Barlesi, F., Califano, R., Cufer, T., Ekman, S., Levra, M. G., Kerr, K., Popat, S., Reck, M., Senan, S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw326 · Cited by 2,631
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Akbay, E. A., Koyama, S., Carretero, J., Altabef, A. B., Tchaicha, J. H., Christensen, C. L., Mikse, O. R., Cherniack, A. D., Beauchamp, E. M., Pugh, T. J., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0310 · Cited by 1,250
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Zhang, Y., Yuan, J.-Q., Wang, K., Fu, X., Han, X., Threapleton, D. E., Yang, Z., Mao, C., & Tang, J.-L. (2016) · Oncotarget · doi:10.18632/oncotarget.12587 · Cited by 866
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Masters, G. A., Temin, S., Azzoli, C. G., Giaccone, G., Baker, S., Brahmer, J. R., Ellis, P. M., Gajra, A., Rackear, N., Schiller, J. H., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1342 · Cited by 850
Checkpoint inhibitors in metastatic EGFR-mutated non–small cell lung cancer-a meta-analysis
Lee, C. K., Man, J., Lord, S., Links, M., Gebski, V., Mok, T., & Yang, J. C.-H. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.007 · Cited by 839
Self-citation
Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation
Chen, N., Fang, W., Zhan, J., Hong, S., Tang, Y., Kang, S., Zhang, Y., He, X., Zhou, T., Qin, T., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000500 · Cited by 681
Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
Hanna, N., Johnson, D., Temin, S., Baker, S., Brahmer, J., Ellis, P. M., Giaccone, G., Hesketh, P. J., Jaiyesimi, I., Leighl, N. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.6065 · Cited by 643

Flagged first, then by citations

Show all 17 references

Sorted by citations

Lung cancer
Thai, A. A., Solomon, B., Sequist, L. V. D., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,753
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Kinase drug discovery 20 years after imatinib: progress and future directions
Cohen, P., Cross, D. A. E., & Janne, P. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00195-4 · Cited by 1,092
Regulatory mechanisms of PD-1/PD-L1 in cancers
Lin, X., Kang, K., Chen, P., Zeng, Z., Li, G., Xiong, W., Yi, M., & Xiang, B. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02023-w · Cited by 909
The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
Yuan, M., Huang, L., Chen, J., Wu, J., & Xu, Q. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0099-9 · Cited by 696
Overcoming therapy resistance in EGFR-mutant lung cancer
Passaro, A., Jänne, P. A., Mok, T., & Peters, S. (2021) · Nature Cancer · doi:10.1038/s43018-021-00195-8 · Cited by 565
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer
Oxnard, G. R., Yang, J. C.-H., Yu, H., Kim, S.-W., Saka, H., Horn, L., Goto, K., Ohe, Y., Mann, H., Thress, K. S., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.013 · Cited by 438
Self-citation
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
Fu, K., Xie, F., Wang, F., & Fu, L. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01391-4 · Cited by 432
Antitumour immunity regulated by aberrant ERBB family signalling
Kumagai, S., Koyama, S., & Nishikawa, H. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-020-00322-0 · Cited by 288
Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations
Lin, A., Wei, T., Meng, H., Luo, P., & Zhang, J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1062-7 · Cited by 266
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects
Tang, S., Qin, C., Hu, H., Liu, T., He, Y., Guo, H., Yan, H., Zhang, J., Tang, S., & Zhou, H. (2022) · Cells · doi:10.3390/cells11030320 · Cited by 273
Tumor cell plasticity in targeted therapy-induced resistance: Mechanisms and new strategies
Shi, Z.-D., Pang, K., Wu, Z.-X., Dong, Y., Hao, L., Qin, J.-X., Wang, W., Chen, Z.-S., & Han, C.-H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01383-x · Cited by 256
Current Landscape of Non-Small Cell Lung Cancer: Epidemiology, Histological Classification, Targeted Therapies, and Immunotherapy
Rodak, O., Peris‐Díaz, M. D., Olbromski, M., Podhorska‐Okołów, M., & Dzięgiel, P. (2021) · Cancers · doi:10.3390/cancers13184705 · Cited by 250
ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer
Passaro, A., Leighl, N. B., Blackhall, F. H., Popat, S., Kerr, K. M., Ahn, M., Arcila, M. E., Arrieta, O. G., Planchard, D., de Marinis, F., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.02.003 · Cited by 209
Self-citation
EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research
Dong, R., Zhu, M., Liu, M., Xu, Y., Yuan, L.-L., Bian, J., Xia, Y., & Kong, L. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105583 · Cited by 211
Advances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Immune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.003 · Cited by 186
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 162
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
To, K. K. W., Fong, W., & Cho, W. C. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.635007 · Cited by 157
Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors: Focus on novel therapies
Johnson, M. L., Garassino, M. C., Mok, T. S. K., & Mitsudomi, T. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.05.011 · Cited by 159
EGFR-Mutated Non-Small Cell Lung Cancer and Resistance to Immunotherapy: Role of the Tumor Microenvironment
Madeddu, C., Donisi, C., Liscia, N., Lai, E., Scartozzi, M., & Macciò, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126489 · Cited by 161
An update on the immune landscape in lung and head and neck cancers
Carlisle, J. W., Steuer, C. E., Owonikoko, T. K., & Saba, N. F. (2020) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21630 · Cited by 144
Therapeutic advances in non‐small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy
Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 131
Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer
Quan, Z., Yang, Y., Zheng, H., Zhan, Y., Luo, J., Ning, Y., & Fan, S. (2022) · Journal of Cancer · doi:10.7150/jca.77619 · Cited by 129
Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
Tu, E., McGlinchey, K., Wang, J., Martin, P., Ching, S., Floc’h, N., Kurasawa, J. H., Starrett, J. H., Lazdun, Y., Wetzel, L. K., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.142843 · Cited by 125
Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer: Current Understanding in Characteristics, Diagnosis, and Management
Zhang, Q., Tang, L., Zhou, Y., He, W., & Li, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663986 · Cited by 121
Immune checkpoint Inhibitor–Induced diarrhea and Colitis: Incidence and Management. A systematic review and Meta-analysis
Nielsen, D. L., Juhl, C. B., Chen, I. M., Kellermann, L., & Nielsen, O. H. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102440 · Cited by 128
Regulation of PD-L1 expression in cancer and clinical implications in immunotherapy.
Ju, X., Zhang, H., Zhou, Z., & Wang, Q. (2020) · PubMed Central · Cited by 108
Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely
Calles, A., Riess, J. W., & Brahmer, J. R. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_280795 · Cited by 111
Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
O’Leary, C. G., Gasper, H. M., Sahin, K. B., Tang, M., Kulasinghe, A., Adams, M. N., Richard, D. J., & O'Byrne, K. J. (2020) · Pharmaceuticals · doi:10.3390/ph13100273 · Cited by 114
Immune Checkpoint Inhibitors Combined with Targeted Therapy: The Recent Advances and Future Potentials
Li, B., Jin, J., Guo, D., Tao, Z., & Hu, X. (2023) · Cancers · doi:10.3390/cancers15102858 · Cited by 108
Clinical Cancer Advances 2021: ASCO's Report on Progress Against Cancer
Smith, S. M., WACHTER, K., Burris, H. A., Schilsky, R. L., George, D. J., Peterson, D. E., Johnson, M. L., Markham, M. J., Mileham, K. F., Beg, M. S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03420 · Cited by 107
The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients
Zhai, X., Zhang, J., Tian, Y., Li, J., Wang, J., Guo, H., & Zhu, H. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0102 · Cited by 99
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
Wright, N. A., & Goss, G. D. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.06.01 · Cited by 95
Exploiting temporal aspects of cancer immunotherapy
Zemek, R. M., Anagnostou, V., da Silva, I. P., Long, G. V., & Lesterhuis, W. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00699-2 · Cited by 96
Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives
Lee, J. M., McNamee, C., Toloza, E. M., Negrao, M. V., Lin, J., Shum, E., Cummings, A. L., Kris, M. G., Sepesi, B., Bāra, I., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.07.006 · Cited by 89
Self-citation
Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial
Ahn, M., Cho, B. C., Ou, X., Walding, A., Dymond, A. W., Ren, S., Cantarini, M., & Janne, P. A. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.01.012 · Cited by 80
A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer
Creelan, B., Yeh, T. C., Kim, S.-W., Nogami, N., Kim, D., Chow, L. Q. M., Kanda, S., Taylor, R., Tang, W., Tang, M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01099-7 · Cited by 75
Self-citation
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
Zhao, Y., He, Y., Wang, W., Cai, Q., Ge, F., Chen, Z., Zheng, J., Zhang, Y., Deng, H., Chen, Y., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00379-6 · Cited by 76
Afatinib and Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (ALPHA Study): A Phase II Study with Biomarker Analysis
Kao, H., Liao, B.-C., Huang, Y., Huang, H., Chen, C., Chen, T., Hong, Y.-J., Chan, C.-Y., Chia, J., & Hong, R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3025 · Cited by 70
Immunotherapy in non-small cell lung cancer: update and new insights
Mielgo-Rubio, X., Uribelarrea, E. A., Cortés, L. Q., & Moyano, M. S. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202101.001 · Cited by 65
Comprehensive analyses reveal TKI-induced remodeling of the tumor immune microenvironment in EGFR/ALK-positive non-small-cell lung cancer
Fang, Y. V., Wang, Y., Zeng, D., Zhi, S., Shu, T., Huang, N., Zheng, S., Wu, J., Liu, Y., Huang, G., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1951019 · Cited by 67
Epidermal growth factor receptor inhibitors as potential anticancer agents: An update of recent progress
Sharma, B., Singh, V. J., & Chawla, P. A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105393 · Cited by 65
Development of pharmacological immunoregulatory anti-cancer therapeutics: current mechanistic studies and clinical opportunities
Yin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 74
Association of Immune Checkpoint Inhibitors With Neurologic Adverse Events
Farooq, M. Z., Aqeel, S. B., Lingamaneni, P., Pichardo, R., Jawed, A., Khalid, S., Banskota, S. U., Fu, P., & Mangla, A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.7722 · Cited by 63
Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer
Wang, Z., Xing, Y., Li, B., Li, X., Liu, B., & Wang, Y. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00107-x · Cited by 62
The Resistance to EGFR-TKIs in Non-Small Cell Lung Cancer: From Molecular Mechanisms to Clinical Application of New Therapeutic Strategies
Laface, C., Maselli, F. M., Santoro, A. N., Iaia, M. L., Ambrogio, F., Laterza, M., Guarini, C., Santis, P. D., Perrone, M., & Fedele, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061604 · Cited by 63
Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer
Tripathi, S. K., Pandey, K., Rengasamy, K. R. R., & Biswal, B. K. (2020) · Medicinal Research Reviews · doi:10.1002/med.21700 · Cited by 54
TP53 Co-Mutations in Advanced EGFR-Mutated Non–Small Cell Lung Cancer: Prognosis and Therapeutic Strategy for Cancer Therapy
Liu, S., Yu, J. S., Zhang, H., & Liu, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.860563 · Cited by 53
Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance
Passarelli, A. M., Aieta, M., Sgambato, A., & Gridelli, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01479 · Cited by 50
Schizandrin A can inhibit non‑small cell lung cancer cell proliferation by inducing cell cycle arrest, apoptosis and autophagy
Zhu, L., Wang, Y., Lv, W., Wu, X. X., Sheng, H., He, C., & Hu, J. (2021) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2021.5047 · Cited by 49
Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data
Marin-Acevedo, J. A., Pellini, B., Kimbrough, E. O., Hicks, J. K., & Chiappori, A. (2023) · Cancers · doi:10.3390/cancers15030629 · Cited by 52
Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study
Bian, D., Sun, L., Hu, J., Duan, L., Xia, H., Zhu, X., Sun, F., Zhang, L., Yu, H., Xiong, Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40349-z · Cited by 49
Self-citation
Improvement strategy for immune checkpoint blockade: A focus on the combination with immunogenic cell death inducers
Shi, F., Huang, X., Hong, Z., Lü, N., Huang, X., Liu, L., Liang, T., & Bai, X. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216167 · Cited by 46
Current Status of Immune Checkpoint Inhibitor Immunotherapy for Lung Cancer
Xiong, W. G., Zhao, Y., Du, H., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.704336 · Cited by 47
Current and Future Treatment Options in the Management of Stage III NSCLC
Li, Y., Juergens, R. A., Finley, C., & Swaminath, A. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.08.011 · Cited by 46
Immunotherapy resistance in solid tumors: mechanisms and potential solutions
Lefler, D. S., Manobianco, S. A., & Bashir, B. (2024) · Cancer Biology & Therapy · doi:10.1080/15384047.2024.2315655 · Cited by 49
Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
García‐Aranda, M., & Redondo, M. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092296 · Cited by 44
Immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: A systematic review
Attili, I., Passaro, A., Corvaja, C., Aliaga, P. T., Signore, E. D., Spitaleri, G., & de Marinis, F. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102602 · Cited by 43
Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients
Liao, B.-C., Griesing, S., & Yang, J. C. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919890286 · Cited by 40
Self-citation
EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer
Huang, H., Zhu, X., Yu, Y., Li, Z., Yang, Y., Xia, L., & Lü, S. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05456-5 · Cited by 38
Immune checkpoint inhibitors in oncogene-addicted non-small cell lung cancer: a systematic review and meta-analysis
Guaitoli, G., Tiseo, M., Maïo, M. D., Friboulet, L., & Facchinetti, F. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-941 · Cited by 38
Design of a Trispecific Checkpoint Inhibitor and Natural Killer Cell Engager Based on a 2 + 1 Common Light Chain Antibody Architecture
Bogen, J. P., Carrara, S. C., Fiebig, D., Grzeschik, J., Hock, B. M., & Kolmar, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669496 · Cited by 36
The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non‐small cell lung cancer patients with epidermal growth factor receptor mutation
Ma, L., Diao, B., Huang, Z., Wang, B., Yu, J., & Meng, X. (2021) · 癌症：英文版 · doi:10.1002/cac2.12229 · Cited by 33
Incidence of Immune Checkpoint Inhibitor-Associated Diabetes: A Meta-Analysis of Randomized Controlled Studies
Lü, J., Yang, J., Liang, Y., Meng, H., Zhao, J., & Zhang, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01453 · Cited by 34
Self-citation
Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response
Kleczko, E. K., Le, A. T., Hinz, T. K., Nguyen, T. T., Navarro, A., Hu, C., Selman, A. M., Clambey, E. T., Merrick, D. T., Lu, S., et al. (2023) · Cancer Letters · doi:10.1016/j.canlet.2023.216062 · Cited by 31
Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer
Wang, S., Hu, C., Xie, F., & Liu, Y. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s235714 · Cited by 32
Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
Russano, M., Cava, G. L., Cortellini, A., Citarella, F., Galletti, A., Fazio, G. R. D., Santo, V., Brunetti, L., Vendittelli, A., Fioroni, I., et al. (2023) · Current Oncology · doi:10.3390/curroncol30020181 · Cited by 34
Afatinib Exerts Immunomodulatory Effects by Targeting the Pyrimidine Biosynthesis Enzyme CAD
Tu, H.-F., Ko, C., Lee, C., Lee, C., Lan, S.-W., Lin, H.-H., Lin, H.-Y., Ku, C., Lee, D., Chen, I., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3436 · Cited by 31
Self-citation
Risk factors for immune‐related adverse events from anti‐PD ‐1 or anti‐ PD‐L1 treatment in an Asian cohort of nonsmall cell lung cancer patients
Huang, Y., Soon, Y. Y., Aminkeng, F., Tay, S. H., Ang, Y. L. E., Kee, A. C.-L., Goh, B. C., Wong, A. S. C., & Soo, R. A. (2021) · International Journal of Cancer · doi:10.1002/ijc.33822 · Cited by 30
Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer
Wang, B., Guo, H., Xu, H., Yu, H., Chen, Y., & Zhao, G. (2021) · Cells · doi:10.3390/cells10102620 · Cited by 29
Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer
Gavralidis, A., & Gainor, J. F. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000491 · Cited by 28
Optimizing Osimertinib for NSCLC: Targeting Resistance and Exploring Combination Therapeutics
Liao, Y.-Y., Tsai, C.-L., & Huang, H. (2025) · Cancers · doi:10.3390/cancers17030459 · Cited by 28
Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
Shi, C., Wang, Y., Xue, J., & Zhou, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.940288 · Cited by 31
Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice
Jia, Y., Zhao, S., Jiang, T., Li, X., Zhao, C., Liu, Y., Han, R., Qiao, M., Liu, S., Su, C., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.09.016 · Cited by 27
Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer
Chen, Y., Chen, Z., Chen, R., Fang, C., Zhang, C., Ji, M. Q., & Yang, X. (2022) · Future Oncology · doi:10.2217/fon-2021-0862 · Cited by 30
Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
Wiest, N. E., Majeed, U., Seegobin, K., Zhao, Y., Lou, Y., & Manochakian, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751209 · Cited by 26
Immune-Related Toxicity in NSCLC: Current State-of-the-Art and Emerging Clinical Challenges
O’Leary, C. L., Pierce, N., Patel, S. P., & Naidoo, J. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.11.018 · Cited by 27
Immuno-Oncology—The New Paradigm of Lung Cancer Treatment
Dawe, D. E., Harlos, C. H., & Juergens, R. A. (2020) · Current Oncology · doi:10.3747/co.27.5183 · Cited by 26
The efficacy and safety of osimertinib in treating nonsmall cell lung cancer
Liu, J., Li, X., Shao, Y., Guo, X., & He, J. (2020) · Medicine · doi:10.1097/md.0000000000021826 · Cited by 25
Durvalumab as Consolidation Therapy in Post-Concurrent Chemoradiation (CCRT) in Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Multicenter Observational Study
Wang, C., Chiu, L., Ju, J., Lin, Y., Fang, Y., Yang, C., & Hsu, P. (2021) · Vaccines · doi:10.3390/vaccines9101122 · Cited by 25
A narrative review of the role of common EGFR mutations in pathogenesis and treatment of non-small-cell lung carcinoma
Sharma, M., Basu, D. A., Nathany, S., Amrith, B. P., & Batra, U. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_222_22 · Cited by 28
A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)
Watanabe, S., Furuya, N., Nakamura, A., Shiihara, J., Nakachi, I., Tanaka, H., Nakao, M., Minato, K., Seike, M., Sasaki, S., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.113469 · Cited by 26
Resistance to immunotherapy in non-small cell lung cancer: Unraveling causes, developing effective strategies, and exploring potential breakthroughs
Dong, S., Li, X., Huang, Q., Li, Y., Li, J., Zhu, X., Xue, C., Chen, R., Zeng, Y., Wu, J., et al. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101215 · Cited by 25
Combinations using checkpoint blockade to overcome resistance
Morganti, S., & Curigliano, G. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1148 · Cited by 25
The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC
Li, S., Zhu, S., Wei, H., Zhu, P., Jiao, Y., Yi, M., Gong, J., Zheng, K., & Zhang, L. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113959 · Cited by 26
CD24 is a promising immunotherapeutic target for enhancing efficacy of third‐generation EGFR‐TKIs on EGFR‐mutated lung cancer
Liang, J., Bi, G., Huang, X., Xu, Z., Huang, Y., Bian, Y., Shan, G., Guo, W., Yan, Y., Sui, Q., et al. (2025) · 癌症：英文版 · doi:10.1002/cac2.70068 · Cited by 29
Shaping the battlefield: EGFR and KRAS tumor mutations’ role on the immune microenvironment and immunotherapy responses in lung cancer
Alsaed, B., Bobik, N., Laitinen, H. K., Nandikonda, T., Ilonen, I., & Haikala, H. M. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10272-4 · Cited by 25
Advances in targeting acquired resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors
Chen, J. A., & Riess, J. W. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.08.32 · Cited by 21
Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
Qian, X., Guo, X., Li, T., Hu, W., Zhang, L., Wu, C., & Ye, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.926890 · Cited by 20
Incidence and Risk of Hematological Adverse Events Associated With Immune Checkpoint Inhibitors: A Systematic Literature Review and Meta-Analysis
Ohashi, T., Takase‐Minegishi, K., Maeda, A., Hamada, N., Yoshimi, R., Kirino, Y., Teranaka, H., Kunimoto, H., Hagihara, M., Matsumoto, K., et al. (2023) · Journal of Hematology · doi:10.14740/jh1090 · Cited by 19
Strategies to Overcome Resistance to Osimertinib in EGFR-Mutated Lung Cancer
Romaniello, D., Morselli, A., & Marrocco, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26072957 · Cited by 20
Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities
Ren, X., Li, Y., Nishimura, C., & Zang, X. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2021.08.009 · Cited by 19
Treatment-Related Adverse Events of Combination EGFR Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor in EGFR-Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
Chan, D., Choi, C., & Lee, V. H.-F. (2022) · Cancers · doi:10.3390/cancers14092157 · Cited by 18
The toxicity associated with combining immune check point inhibitors with tyrosine kinase inhibitors in patients with non-small cell lung cancer
Kalra, A., & Rashdan, S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1158417 · Cited by 19
EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy
Gu, Y., He, H., Qiao, S., Shao, Y., Wang, L., Zhang, Z., Zhang, L., & Zhou, F. (2025) · Advanced Science · doi:10.1002/advs.202505785 · Cited by 19
Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients
Hsu, K.-H., Huang, J.-W., Tseng, J., Chen, K., Weng, Y.-C., Yu, S., Yang, T., Huang, Y.-H., Chen, J. J. W., Chen, K., et al. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s300267 · Cited by 17
Self-citation
Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
Lee, J., Piotrowska, Z., Soo, R. A., Cho, B. C., & Lim, S. M. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221144099 · Cited by 17
Self-citation
Treatment of advanced non-small cell lung cancer with driver mutations: current applications and future directions
Zhong, J., Bai, H., Wang, Z., Duan, J., Zhuang, W., Wang, D., Wan, R., Xu, J., Fei, K., Ma, Z., et al. (2023) · Frontiers of Medicine · doi:10.1007/s11684-022-0976-4 · Cited by 19
Therapeutic role of EGFR - Tyrosine kinase inhibitors in non-small cell lung cancer with leptomeningeal metastasis
Jia, C., Xu, Q., Zhao, L., Kong, F., & Jia, Y. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101832 · Cited by 17

Authors: Yang, J. C.-H., Shepherd, F. A., Kim, D.-W., Lee, G.-W., Lee, J. S., Chang, G.-C., Lee, S. S., Wei, Y.-F., Lee, Y. G., Laus, G., Collins, B., Pisetzky, F., & Horn, L.
Affiliations: National Taiwan University Hospital (TW)
University of Toronto (CA)
Seoul National University (KR)
Gyeongsang National University (KR)
Taichung Veterans General Hospital (TW)
Inje University (KR)
E-Da Hospital (TW)
Kangbuk Samsung Hospital (KR)
AstraZeneca (United Kingdom) (GB)
AstraZeneca (Netherlands) (NL)
Vanderbilt University Medical Center (US)
Corresponding author: Yang, James Chih-Hsin
ORCID: Yang, James Chih-Hsin
Shepherd, Frances A.
Kim, Dong-Wan
Lee, Gyeong-Won
Lee, Jong Seok
Wei, Yu-Feng
Collins, Barbara
Horn, Leora
Venue: Journal of Thoracic Oncology
Publisher: Elsevier BV
Published: 2019-05
Volume: 14
Issue: 5
Pages: 933-939
ISSN: 1556-0864 (ISSN-L)
DOI: 10.1016/j.jtho.2019.02.001
OpenAlex: W2912107322
Cited by: 210
References: 17
Citations by year: 2026: 15 · 2025: 20 · 2024: 24 · 2023: 30 · 2022: 39 · 2021: 42 · 2020: 27 · 2019: 13
FWCI: 22.23
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
Locations: Journal of Thoracic Oncology (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Seoul National University Open Repository (Seoul National University) (submittedVersion)
Funders: Meso Scale Diagnostics
Takeda Pharmaceuticals North America
AstraZeneca
EMD Serono (NCT02454933)
Bayer
Celgene
Eli Lilly and Company
Daiichi Sankyo Company
AbbVie
Bristol-Myers Squibb
Pfizer
Novartis
Astellas Pharma Canada
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Keywords: osimertinib, durvalumab, T790M mutation, non-small cell lung cancer, EGFR tyrosine kinase inhibitor resistance, immune checkpoint inhibitors, interstitial lung disease, safety and tolerability, combination therapy
MeSH terms: Acrylamides, Adult, Aged, Aged, 80 and over, Aniline Compounds, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Pyrimidines, Protein Kinase Inhibitors, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks